ClinicalTrials.gg
CompletedNCT02827903Updated Jul 6, 2018

Metformin/Rosuvastatin Combination Therapy With in Patients With Type 2 Diabetes and Dyslipidemia

A Phase 3 interventional study of Metformin + Rosuvastatin and Metformin + placebo in Type 2 Diabetes and Dyslipidemia, sponsored by Jeil Pharmaceutical Co., Ltd.. Completed at 33 sites in Korea, Republic of. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2018-07-06.

Sponsored by Jeil Pharmaceutical Co., Ltd. · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 5 months after the study started (first participant enrolled Jan 2016, registered Jun 2016).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
237
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 293 studies testing metformin in Diabetes Mellitus, Type 2 — 17 open to participants now, 22 under way, 2 of them phase 3. Metformin · Diabetes Mellitus, Type 2.

Enrollment
83rd of 287
237 · median 100
Started
2016
with 12 others
Phase 3
72 of 293
1 open now
Registered
216th of 293
by date

Among the 293 studies testing metformin in Diabetes Mellitus, Type 2, this one is the 83rd largest by enrollment of the 287 interventional ones that give a count, is one of 13 that started in 2016, is one of 72 in phase 3, and was the 216th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

17 of the 293 studies testing metformin in Diabetes Mellitus, Type 2 are open now, in 7 countries. Recruiting first, the newest first:

12 more — sign in →

By country, each count listing its studies:

All 17 open studies →

About metformin

Metformin: first FDA approval 1995 (GLUCOPHAGE), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 293 studies testing metformin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

Compare the Efficacy and Safety of Metformin/Rosuvastatin Combination Therapy With Metformin or Rosuvastatin Monotherapy in Patients With Type 2 Diabetes and Dyslipidemia

Read the detailed description

Multi-center, Randomized, Double-blind, Phase III clinical trial

03

Conditions studied

  • Type 2 Diabetes
  • Dyslipidemia

Keywords

  • Metformin
  • Rosuvastatin
  • type 2 diabetes
  • dyslipidemia
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Over 19 years
  • Type II DM with Dyslipidemia
  • 6.5% ≤ \< 11%
  • Triglyceride \< 350mg/dL
  • 100mg/dL ≤ LDL-C ≤ 250mg/dL
  • FPG ≤ 270mg/dL

Exclusion criteria

Exclusion Criteria:

  • Type I DM
  • Unstable angina, MI, Stroke, CABG with 6 month from screening
  • SBP ≥ 180mmHg, DBP ≥ 110mmHg
  • TSH > UNL
  • Heart failure ( class III/IV)
  • Serum Creatinine > UNL or CLCr \< 60 mL/min
  • CK ≥ 2x UNL
  • positive
  • > 40 kg/m\^2
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
237 participants (actual)

Study arms

  • Experimental
    Group I

    Metformin + Rosuvastatin, Dosing to Type II DM with Dyslipidemia

    Drug: Metformin + Rosuvastatin

  • Active comparator
    Group II

    Metformin + placebo, Dosing to Type II DM with Dyslipidemia

    Drug: Metformin + placebo

  • Active comparator
    Group III

    Placebo + Rosuvastatin, Dosing to Type II DM with Dyslipidemia

    Drug: placebo + Rosuvastatin

Interventions

  • DrugMetformin + Rosuvastatin

    Drug pages: Metformin · Rosuvastatin

    Group I: Metformin + Rosuvastatin,

  • DrugMetformin + placebo

    Group II: Metformin + placebo,

  • Drugplacebo + Rosuvastatin

    Group III: placebo + Rosuvastatin

06

What researchers measure

Primary outcomes

  1. LDL-C (% change)

    Time frame: 16 weeks from baseline

  2. change of HbA1c

    Time frame: 16 weeks from baseline

07

Study locations

33 sites
  • Buchoen St. mary's Hospital
    Bucheon, Korea, Republic of
  • SeJong Hostpital
    Bucheon, Korea, Republic of
  • SoonChunHyang University Bucheon Hospital
    Bucheon, Korea, Republic of
  • InJe University Busan paik Hospital
    Busan, Korea, Republic of
  • Inje University Haeundae paik hospital
    Busan, Korea, Republic of
  • Daegu Catholic University Medical Center
    Daegu, Korea, Republic of
  • Youngnam University Hostpital
    Daegu, Korea, Republic of
  • Daeheon Eulji Medical Center
    Daejeon, Korea, Republic of
  • KonYang University Hostpital
    Daejeon, Korea, Republic of
  • Chosun University Hospital
    Gwangju, Korea, Republic of
  • BunDang Jesang Hospital(DMC)
    Gyeonggi-do, Korea, Republic of
  • Hallym University Sacred Heart hospital
    Gyeonggi-do, Korea, Republic of
  • HanYang University Guri Hospital
    Gyeonggi-do, Korea, Republic of
  • Inje University Ilsan paik hospital
    Gyeonggi-do, Korea, Republic of
  • Myoung Ji Hospital
    Gyeonggi-do, Korea, Republic of
  • Gachon Gil Hospital
    Incheon, Korea, Republic of
  • Inchoen St. mary's Hospital
    Incheon, Korea, Republic of
  • Eulji Hospital Nowon
    Seoul, Korea, Republic of
  • Hallym University Kangnam Sacred Heart hospital
    Seoul, Korea, Republic of
  • KangBuk SamSung Hospital
    Seoul, Korea, Republic of
  • Kangdong Sacred Heart Hospital
    Seoul, Korea, Republic of
  • KonKuk University Medical Center
    Seoul, Korea, Republic of
  • Korea University Anam Hospital
    Seoul, Korea, Republic of
  • KyungHee University Hospital at Gangdong
    Seoul, Korea, Republic of
  • Samsung Medical Center
    Seoul, Korea, Republic of
  • Seoul National University Hospital(Famlily medicine)
    Seoul, Korea, Republic of
  • Seoul National University Hospital
    Seoul, Korea, Republic of
  • Severance hospital
    Seoul, Korea, Republic of
  • SoonChunHayng University Hospital Seoul
    Seoul, Korea, Republic of
  • The catholic University of Korea YEOUIDO St mary's Hospital
    Seoul, Korea, Republic of
  • Korea University Guro hospital
    Soeul, Korea, Republic of
  • Ajou University hospital
    Suwon, Korea, Republic of
  • Wonju Severance Christian hospital
    Wŏnju, Korea, Republic of
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2016 to primary completion in Nov 2017, 22 months.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 22 months is above that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 23, 2016
First posted
Jul 11, 2016
StartActual
Jan 15, 2016
Primary completionActual
Nov 21, 2017
CompletionActual
Mar 16, 2018
Last update
Jul 6, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 6, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02827903
Responsible party
Sponsor
First posted
Jul 11, 2016
Start date
Jan 15, 2016
Primary completion
Nov 21, 2017
Completion
Mar 16, 2018
Last update
Jul 6, 2018

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Metformin · Rosuvastatin

Start the discussion